Keymed Biosciences, Inc. (2162) AI Stock Analysis

• Market Cap: HK$20.43B
• Dividend Yield: N/A
• Average Volume (3M): 4.85M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: 964.40%
• EPS Growth: 65.90%
• Country: HK
• Employees: 1,258
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 298,735,570
• 10 Day Avg. Volume: 3,286,161
• 30 Day Avg. Volume: 4,851,500
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$66.00
• Price Target Upside: -0.75% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: HK$66.00 ▼(-0.75% Downside)

Keymed Biosciences, Inc. scores moderately due to strong technical momentum but is weighed down by negative financial performance and poor valuation metrics. The financial performance presents a significant risk with ongoing losses and cash flow issues, while technical indicators are currently favorable, suggesting short-term gains. Valuation concerns due to the negative P/E ratio also impact the score.

Keymed Biosciences, Inc. Business Overview & Revenue Model

Company Description

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.

How the Company Makes Money

Keymed Biosciences makes money through the development and commercialization of its proprietary therapeutics. The company's revenue model is primarily based on the sales of its biopharmaceutical products once they receive regulatory approval. Additionally, Keymed may engage in strategic partnerships, collaborations, and licensing agreements with other pharmaceutical companies, which can provide milestone payments, royalties, and co-development funding. These partnerships often enhance the company's financial stability and expand the market reach of its products. Research and development grants or subsidies from governmental and non-governmental organizations may also contribute to the company's earnings.

Keymed Biosciences, Inc. Financial Statement Overview

Summary

Keymed Biosciences, Inc. shows significant revenue growth, yet operates at a loss with negative net profit and EBIT margins. Despite a strong equity position and low leverage, negative cash flows and net losses are concerning for financial sustainability.

Income Statement

Keymed Biosciences, Inc. has shown significant revenue growth from 2022 to 2024, with revenue increasing from 100 million to 428 million. However, the company is still operating at a loss, with a negative net profit margin and EBIT margin. The gross profit margin is high, indicating good product profitability, but this is offset by high operating expenses leading to negative net income.

Balance Sheet

The company maintains a strong equity position with a debt-to-equity ratio below 0.5, indicating low leverage. However, the ROE is negative due to consistent net losses. The equity ratio is healthy, suggesting a strong asset base compared to liabilities, which is crucial for future growth and stability.

Cash Flow

The free cash flow remains negative, reflecting high capital expenditures and operating losses. There is an absence of operating cash flow, highlighting challenges in converting revenue into cash. The company has not demonstrated positive cash flow to net income ratios, which are critical for long-term financial health.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	428.12M	354.10M	100.06M	110.27M	0.00
Gross Profit	415.92M	317.22M	97.48M	93.07M	0.00
EBITDA	-574.46M	-269.77M	-259.25M	-3.86B	-785.71M
Net Income	-515.24M	-359.36M	-308.12M	-3.90B	-832.73M
Balance Sheet
Total Assets	3.77B	3.88B	3.93B	3.93B	529.95M
Cash, Cash Equivalents and Short-Term Investments	2.16B	2.72B	3.18B	3.52B	354.08M
Total Debt	753.24M	418.71M	121.97M	39.26M	66.86M
Total Liabilities	1.29B	896.11M	593.10M	289.07M	1.62B
Stockholders Equity	2.47B	2.99B	3.34B	3.65B	-1.09B
Cash Flow
Free Cash Flow	-1.00B	-686.23M	-681.48M	-387.50M	-139.26M
Operating Cash Flow	-789.63M	-303.62M	-401.93M	-214.64M	-119.36M
Investing Cash Flow	67.71M	468.20M	-645.59M	-2.04B	-113.07M
Financing Cash Flow	283.90M	72.13M	-8.06M	3.64B	7.40M

Keymed Biosciences, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 66.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2162, the sentiment is Positive. The current price of 66.5 is below the 20-day moving average (MA) of 69.39, above the 50-day MA of 58.53, and above the 200-day MA of 43.45, indicating a neutral trend. The MACD of 3.60 indicates Positive momentum. The RSI at 49.67 is Neutral, neither overbought nor oversold. The STOCH value of 34.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2162.

Keymed Biosciences, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2315	66 Neutral	HK$8.84B	229.90	4.16%	―	34.39%	―
1672	58 Neutral	HK$14.01B	―	-12.74%	―	-76.58%	-4.90%
2157	57 Neutral	HK$17.49B	―	-21.42%	―	240.05%	-140.09%
2162	55 Neutral	HK$20.43B	―	-8.79%	―	964.40%	65.90%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
2096	―	HK$35.73B	37.41	12.36%	1.30%	―	―
2171	53 Neutral	HK$12.93B	―	-42.47%	―	1219.19%	25.12%

Keymed Biosciences, Inc. Corporate Events

Keymed Biosciences Schedules Board Meeting to Review Interim Results

Keymed Biosciences Inc. has announced a board meeting scheduled for August 26, 2025, to review and approve the interim financial results for the first half of the year and consider the payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and potential shareholder returns, impacting its market positioning and stakeholder interests.

Keymed Biosciences Announces Successful AGM Resolutions

Keymed Biosciences Inc. announced that all resolutions proposed at its Annual General Meeting held on June 26, 2025, were passed as ordinary resolutions. The resolutions included the adoption of financial statements, re-election of directors, re-appointment of auditors, and granting of mandates to the board for share issuance and repurchase. This successful meeting indicates strong shareholder support and positions the company for continued strategic operations and governance.

Keymed Biosciences Completes Share Placement and Subscription, Raising HK$853.77 Million

Keymed Biosciences Inc. has completed a placing and subscription of shares, raising approximately HK$853.77 million in net proceeds. The funds will be allocated to research and development, commercialization efforts, capital expenditure for manufacturing and R&D facilities, and general corporate purposes. This financial maneuver is expected to bolster the company’s operational capabilities and enhance its market position in the biotechnology sector.

Keymed Biosciences Announces Share Placement and Subscription to Raise HK$853.77 Million

Keymed Biosciences, Inc. has announced a strategic financial move involving the placing of existing shares and a top-up subscription of new shares. The company plans to sell 21.6 million shares at a discounted price, while issuing 19 million new shares to raise approximately HK$853.77 million in net proceeds. These funds are intended for research and development, commercialization of products, and general corporate purposes. This move is expected to slightly reduce the shareholding of the top-up vendor and potentially strengthen Keymed’s financial position, aiding in its growth and development within the biotechnology sector.